Laseroptek 2026 Q1 Results: Revenue Growth, Operating Loss Narrowing, Rights Offering Completed
Separate revenue in Q1 2026 reached 6.29 billion won, up 19.4% YoY (5.27 billion), operating loss narrowed to 1.16 billion won from 1.31 billion won.
Consolidated Q1 revenue 6.36 billion won, operating loss 1.95 billion won, net loss 1.18 billion won.
Completed rights offering in April 2026 (2.58 million shares at 3,965 won), raising approx. 10.2 billion won, listing scheduled for May.
Lawsuit involving subsidiary LASEROPTEK AMERICA: sued by Strata Skin Sciences; plaintiff delisted from Nasdaq; company filed counterclaim. Outcome uncertain.
New product VasCura589 (vascular disease treatment laser) received MFDS approval.
Consolidated allowance for doubtful accounts on trade receivables 4.28 billion won (37.2% ratio), net debt 2.06 billion won, gearing ratio 8.96% (end of prior year 5.58%).
Consolidated accumulated deficit 17.29 billion won, total equity 20.88 billion won. No share buyback or dividend plan.